Telecom Italia[e] reported good underlying results, however, we were disappointed by the results on a reported basis as well as by cash flow generation. Based on provided guidance, financials will improve. Nevertheless, we doubt Telecom Italia will be investment grade rated in the near future.
AUCTUS PUBLICATIONS ________________________________________ ADX Energy (ADX AU)C; Target price of A$0.30 per share: High production at Z&G. Low risk exploration drilling in Austria to start in 4Q25/1Q26 – 2Q25 net production of 303 boe/d was higher than our expectations of ~270 boe/d following a 5 well intervention programme at the Zisterdorf and Gaiselberg fields in the Vienna Basin. The programme included (1) repair of subsurface equipment, (2) clean out of a down hole sand control (3) perfor...
Two Directors at Telecom Italia Spa sold 1,241,280 shares at between 0.421EUR and 0.426EUR. The significance rating of the trade was 89/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
BioNTech veröffentlicht Ergebnisse für das zweite Quartal 2025 sowie Informationen zur Geschäftsentwicklung BioNTech treibt Onkologiestrategie voran, u.a. mit zwei bekanntgegeben Transaktionen, und setzt damit den Fokus auf die zwei tumorübergreifenden (Pan-Tumor-)Programme: mRNA-Krebsimmuntherapie-Kandidaten und BNT327, ein gegen PD-L11 und VEGF-A gerichteter bispezifischer AntikörperkandidatAbschluss einer globalen strategischen Kollaborationsvereinbarung mit Bristol Myers Squibb („BMS“) zur gemeinsamen Durchführung eines umfangreichen klinischen Entwicklungsprogramms zur Evaluierung und ...
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L11 and VEGF-AEntered a global strategic co-development and co-commercialization collaboration with Bristol Myers Squibb (“BMS”) to jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor typesAnnounced strategic transaction to acquire ...
ELO: overview of H1 results and further details on the new financing structure|Takeover rumours around JD.com and Ceconomy become (more) concrete|Nexity reassures in H1 2025 with numerous positive signs, even though business remains weak|Entry into exclusive negotiations for the joint acquisition of the Milleis Group|
ELO : commentaires résultats S1 et précisions sur la nouvelle structure de financement|Takeover rumours around JD.com and Ceconomy become (more) concrete|Nexity rassure au S1 2025 avec de nombreux signaux positifs, même si l’activité reste faible|Entrée en négociations exclusives en vue de l’acquisition conjointe du Groupe Milleis|
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.